AIM: To observe the efficacy and safety of intravitreal injection of Conbercept for the treatment of wet age-related macular degeneration(AMD).

METHODS: Retrospective analysis. A total of 20 patients involving 22 eyes were diagnosed of wet AMD and confirmed by routine ophthalmic examination, fundus fluorescein angiography(FFA)and optical coherence tomography. All these affected eyes received intravitreal injection of 10 mg/ml of 0.5mg Conbercept, once monthly, for 3 successive times during the initial treatment. The need for repeated treatment was determined according to patients' disease conditions. The patients were followed up once monthly for ≥6mo. The changes in best corrected visual acuity(BCVA), central retinal thickness(CRT)and choroidal neovascularization(CNV)lesion leakage of the affected eyes before and after treatment were compared and analyzed.

RESULTS:Within 1, 3 and 6mo after treatment, the mean BCVA(logMAR)of the affected eyes increased when compared with before treatment; the difference was statistically significant(P<0.01). In 1, 3 and 6mo after treatment, the mean CRT of the affected eyes decreased when compared with before treatment; the difference was statistically significant(P<0.01). During the last follow-up, FFA showed that macular CNV lesion leakage disappeared in 20 eyes(90%)while leakage mitigated in 2 eyes(9%). During the follow-up, there were no treatment-related serious ocular complications and systemic serious adverse reactions.

CONCLUSION:Clinically, intravitreal injection of Conbercept for the treatment of wet AMD can increase visual acuity of the affected eyes. It also can decrease CRT of the affected eyes, and inhibit neovascular leakage. There are no treatment-related adverse reactions.